PRAMOMOLECULAR   is developing novel gene silencing therapies for the treatment of currently "incurable" diseases. Our covalently linked, lipid-based delivery molecules transport nucleic acid-based drugs (NABDs) into lung, heart and pancreatic cells in vivo. Using our "self-delivering siRNAs", which are a highly innovative class of drugs, we can efficiently down-regulate disease-causing proteins such as mutated or over-expressed proteins. This is of great interest because siRNAs can downregulate any disease-causing protein.

The goal of PRAMOMOLECULAR is to provide well-tolerated and effective therapeutics to patients with serious diseases. Our first drug candidates target diseases such as non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and heart failure.

Beside developing our own drug candidates, we are also interested in co-developing and licensing our delivery technology to other developers of NABDs for specific applications.

Investment Information Sheet (IIS) in accordance with Sections 2a and 13 of the German Investment Products Act (VermAnlG) of PRAMOMOLECULAR GmbH


This document is an English translation of the original German version of the Vermögensanlagen-Informationsblatt (VIB). It is provided for informational purposes only and has no legal or official meaning. In case of any discrepancies or legal relevance, only the German version shall be binding.

PRAMOMOLECULAR  supported by